Regulatory status (last updated May 24, 2026):

FDA proposed rule published April 30, 2026. Comment period closes June 29, 2026. Compounded semaglutide is currently LEGAL via 503A pharmacies. 503B bulk compounding faces likely restriction.

FDA Regulatory News

Is compounded semaglutide still legal in 2026?

FDA published a proposed rule on April 30, 2026 to remove semaglutide and tirzepatide from the 503B bulk drug substances list. The 60-day comment period closes June 29. Here is the current legal status, the timeline, and what to do if you are on compounded GLP-1.

By Priya Sharma, NP6 min read

Reviewed by Jane Novak, MD, MPH

Timeline of events

  • October 2024: FDA declares semaglutide shortage resolved. 503B wind-down clock starts.
  • September 2025+: FDA enforcement letters target compounded-drug marketing equivalence claims.
  • April 30, 2026: FDA publishes proposed rule excluding semaglutide + tirzepatide + liraglutide from 503B bulks list.
  • May 1, 2026: Federal Register entry published. 60-day comment clock starts.
  • June 29, 2026: Comment period closes.
  • August-October 2026 (estimated): Final rule, revised proposal, or withdrawal.
  • If finalized: 503B facilities have 90-180 days to wind down. 503A patient-specific compounding continues separately.

503A vs 503B — why it matters

503A pharmacies are state-licensed traditional pharmacies that compound per-patient with an individual prescription. They are governed by section 503A of the FDCA and are NOT directly affected by the April 30 proposed rule.

503B outsourcing facilities are FDA-registered commercial compounders producing drugs in bulk for telehealth platforms without per-patient prescriptions. Section 503B governs. This is the target.

Most lower-priced ($99-199/mo) compounded GLP-1 telehealth services are 503B-supplied. Higher-priced ($250-400/mo) per-prescription services are 503A-supplied. The rule targets the cheap tier.

What to do if you're on compounded GLP-1

  1. 1. Confirm your supply chain. Ask your provider: "Is my medication 503A or 503B sourced?" Reputable services disclose this in onboarding.
  2. 2. Price the brand alternatives. Oral Wegovy via Hims is $149-299/mo. Foundayo via LillyDirect is $349-499/mo.
  3. 3. Document baseline. Weight, labs, current dose — your prescriber needs a clean record before any switch.
  4. 4. Do NOT order from international/unregulated sources. Quality and safety unverifiable.
  5. 5. File a prior auth for brand-name if eligible. Use our prior auth letter generator.

Cheapest legitimate brand-name GLP-1 in 2026

Oral Wegovy via Hims & Hers: $149/month — first FDA-approved branded GLP-1 priced below most compounded alternatives.

See Hims review →

FAQ

Is compounded semaglutide still legal?
Yes, as of May 24, 2026 — patient-specific 503A pharmacy compounding remains legal. The April 30 FDA proposed rule targets 503B bulk compounding only. Final rule expected late 2026.
When does the FDA comment period close?
June 29, 2026 — 60 days after the April 30 publication of the proposed rule in the Federal Register.
Will my Mochi/Eden/Henry Meds prescription stop working?
503B-supplied programs (Hims, Ro, LifeMD, Noom compounded tracks) face wind-down within 90-180 days of any final rule. 503A-supplied per-prescription compounding likely continues — confirm with your provider.
What are the brand-name alternatives if compounded ends?
Hims oral Wegovy $149/mo, LillyDirect Foundayo $349-499/mo, Wegovy Novo savings card $499/mo, Medicare GLP-1 Bridge $50/mo from July 1. See our brand-name comparison.
Should I stockpile compounded semaglutide now?
Most 503A pharmacies do not allow stockpiling. If your prescriber agrees, a 90-day fill is the maximum. Do NOT order from unregulated international sources — quality and safety not verified.

Regulatory update: This page is updated as the FDA rule progresses. Check back after June 29 for post-comment-period analysis. Affiliate-funded but editorially independent.

Related